ASSEMBLY BIOSCIENCES, INC.

Assembly Biosciences is a biotechnology company developing antiviral therapeutic candidates targeting herpes simplex virus, hepatitis B virus, hepatitis delta virus, and transplant-related herpesviruses. The company's pipeline comprises several early-stage programs: ABI-5336 and ABI-1179, helicase-primase inhibitors in Phase 1a/1b development for recurrent genital herpes; ABI-4334, a capsid assembly modulator in Phase 1b clinical study designed to disrupt hepatitis B virus replication; ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a; and ABI-7423, an oral broad-spectrum polymerase inhibitor targeting transplant-related herpesviruses.

The company operates with 73 full-time employees and is headquartered in South San Francisco, California. Assembly Biosciences maintains a research and development collaboration with Gilead Sciences through an option, license, and collaboration agreement for virology therapeutic development. The company was incorporated in Delaware in 2005, originally operating under the name Ventrus Biosciences before rebranding to Assembly Biosciences in 2014. As a clinical-stage biotechnology company, the organization is currently focused on advancing its drug candidates through early clinical trials rather than generating revenue from marketed products.